One of the vital aspects of active pharma is its contribution to the development of new and effective treatments. With the increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular conditions, the demand for innovative medications has surged. Pharmaceutical companies are continuously investing in research and development (R&D) to discover novel APIs that can address unmet medical needs. This focus on innovation is coupled with advancements in technology, including biotechnology and nanotechnology, which have opened new avenues for drug development.
In recent years, natural supplements have surged in popularity, with many individuals seeking alternatives to conventional medicine for various health issues. Among these supplements, berberine and MicroPQQ (Pyrroloquinoline Quinone) have garnered significant attention for their potential benefits, particularly in metabolic health and cellular energy production.
Following successful pilot testing, the full-scale manufacturing process begins. This stage involves the production of APIs in larger quantities, adhering to Good Manufacturing Practices (GMP) to maintain quality control throughout. During this phase, raw materials are procured, and the production facilities are equipped to handle large-scale operations. Automated systems are often implemented to enhance efficiency and minimize errors.